B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
Stocks · News reference
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Perspective Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.